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Abstract
Autophagy is a cellular process leading to the degradation of cytoplasmic components such as organelles and
intracellular pathogens. It has been shown that HIV-1 relies on several components of the autophagy pathway for
its replication, but the virus also blocks late steps of autophagy to prevent its degradation. We generated stable
knockdown T cell lines for 12 autophagy factors and analyzed the impact on HIV-1 replication. RNAi-mediated
knockdown of 5 autophagy factors resulted in inhibition of HIV-1 replication. Autophagy analysis confirmed a
specific defect in the autophagy pathway for 4 of these 5 factors. We also scored the impact on cell viability, but
no gross effects were observed. Upon simultaneous knockdown of 2 autophagy factors (Atg16 and Atg5), an
additive inhibitory effect was scored on HIV-1 replication. Stable knockdown of several autophagy factors inhibit
HIV-1 replication without any apparent cytotoxicity. We therefore propose that targeting of the autophagy pathway
can be a novel therapeutic approach against HIV-1
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Background
Autophagy is a cellular process leading to the degrada-
tion of cytoplasmic components, such as long-lived pro-
teins and organelles [1]. The process starts with the
engulfment of portions of the cytoplasm within a phago-
phore, eventually forming a double-membrane organelle
called the autophagosome (Figure 1). The autophago-
some subsequently fuses with lysosomes and the con-
tents are degraded. Autophagy is mostly known as a
cellular recycling mechanism in the event of nutrient
starvation, but the process has also been implicated in i.
e. developmental control, tissue homeostasis, tumor sup-
pression and antigen-presentation [2-5]. Autophagy has
several functions in immunity, as it not only eliminates
cellular components, but intracellular pathogens like
viruses as well. Not surprisingly, several viruses have
evolved countermeasures to evade or neutralize this
pathway [6,7]. For example, herpes simplex virus 1
(HSV-1) blocks two steps in the autophagy pathway
with a single viral protein: ICP34.5, thereby preventing
degradation of newly formed virus [8,9].
O nt h eo t h e rh a n d ,s o m ev i r uses need autophagy to
complete their replication cycle. Several positive-
stranded RNA viruses such as poliovirus remodel intra-
cellular membrane structures as scaffolds for their repli-
cation machinery [10]. These membranous structures
are thought to be autophagic vacuoles. For influenza A
virus, two studies highlight two different aspects of the
complex interaction between the invading virus and
autophagy. One study reported that the intracellular
concentration of autophagy marker protein LC3-II
increased during influenza virus infection and pharma-
cological inhibition of autophagy reduced the viral titers,
indicating that influenza requires autophagy [11]. How-
ever, it has also been shown that influenza virus arrests
autophagosome degradation, for which the viral M2 pro-
tein is solely responsible. This block of autophagy makes
the infected cells more susceptible to apoptosis [12].
In case of human immunodeficiency virus type 1
(HIV-1), it is not clear to what extent autophagy influ-
ences the viral replication cycle, or whether the virus
influences the autophagy pathway. It has been reported
that the expression of HIV-1 Envelope protein (Env) on
the surface of infected cells induces autophagy in
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fusion [13]. The induction of autophagy subsequently
leads to death of these uninfected cells [13,14]. This
mechanism has been used to explain the so-called
“bystander-effect”, which is the massive depletion of
uninfected cells in HIV-1 infected individuals. Two stu-
dies also indicated that HIV-1 inhibits autophagy in the
infected CD4
+ T cell, shown by reduced expression of
the two autophagy marker proteins LC3 and Beclin1
and analysis of infected cells by electron microscopy
[15,16]. Furthermore, the viral Nef protein prevents
destruction of HIV-1 components in autolysosomes,
thus blocking the antiviral role of autophagy in macro-
phages [17]. Several autophagy factors were identified in
a transient genome-wide RNAi screen for cellular co-
factors of HIV-1 replication [18], suggesting that HIV-1
also needs autophagy or at least some of its components
to complete the replication cycle. Indeed, stable knock-
down of one of the identified autophagic co-factors,
Atg16, resulted in long-term inhibition of HIV-1 replica-
tion [19]. Also in primary cells it has been shown that
several autophagy factors, e.g. Beclin1, Atg5 and Atg7
are required for HIV-1 replication [17,20]. If HIV-1
indeed requires autophagy for its replication, inhibiting
the pathway could be of therapeutic use. Since the virus
relatively easily gains resistance against drugs targeting
viral components, it has been hypothesized that target-
ing of cellular co-factors would make it more difficult
for the virus to gain resistance [21,22]. Therefore we
sought to inhibit several autophagy factors (ATGs) via
RNA interference (RNAi). Stable knockdown cell lines
were generated, each cell line expressing a short hairpin
RNA (shRNA) against a specific mRNA encoding an
autophagy factor. Thirteen autophagy factors were
tested, distributed along the autophagy pathway (Figure
1). Atg1/unc-51-like kinase (ULK1) is required for the
initiation of autophagy. Autophagosome biogenesis is
coordinated by the phosphatidylinositol 3-kinase (PIK3)
complex containing the PIK3 p100 subunit (PIK3C3)
and the PI3K p150 subunit (PIK3R4), which associate
with Beclin1. WIPI1 regulates the transport of phospha-
tidylinositol-3-phosphate to the membranes. Two ubi-
quitin-like conjugation complexes are required; the first
one forms a complex between Atg5 and Atg12, and
Atg16 is non-covalently bound to this complex in a pro-
cess that is catalyzed by Atg7 and Atg10. In the second
conjugation system, LC3 is cleaved by Atg4 cystein pro-
teases, essentially Atg4A and Atg4B, making it possible
for Atg7 and Atg3 to generate the phosphatidylethanola-
mine (PE)-bound form of LC3: LC3-II.
We show that HIV-1 replication can be delayed in
stable ATG knockdown cell lines. An additive inhibitory
effect was observed when two ATGs were knocked
down simultaneously, thus stressing the therapeutic
potential of this strategy. Importantly, this HIV-1 repli-
cation delay was not accompanied by RNAi-induced
cytotoxicity, suggesting that autophagy can be targeted
in host cells without serious side effects.
Results
Stable knockdown of ATG proteins inhibits HIV-1
replication
To test whether stable knockdown of individual autop-
hagy factors has an effect on HIV-1 replication, we gen-
erated cell lines expressing a single shRNA against a
specific mRNA encoding one of the 12 autophagy fac-
tors (ATGs). Per autophagy factor 4 or 5 shRNAs were
tested, resulting in 61 cell lines including 2 controls.
The controls were the empty lentiviral vector SHC1 and
the vector encoding a scrambled shRNA without a
known mRNA target (SHC2). Testing of multiple
shRNAs per ATG has several advantages. First, it allows
one to score a similar phenotype for different shRNAs
that target the same factor, which helps to determine
whether the effect is specific. Second, as different
shRNAs provide different knockdown efficiencies, the
chance that at least one shRNA induces a sufficient
knockdown of the specific target increases. To increase
the chance of observing antiviral activity, we used a rela-
tively high multiplicity of infection (MOI) of the
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Figure 1 Autophagy factors and their function in the
autophagy pathway. Autophagy can be induced by e.g. starvation
signals. Two complexes are needed to form the phagophore. One
includes ULK1, the other the class III phosphatidylinositol 3-kinase
(PIK3C3), PIK3R4 and Beclin 1, together with WIPI1. To form the
autophagosome, two conjugation systems play a role. The Atg12-
Atg5 system forms a complex with non-covalently bound Atg16.
The conjugation of LC3-I (LC3 cleaved by Atg4) with PE generates
LC3-II. This process requires Atg7 and Atg3. The Atg12-Atg5-Atg16
complex is detected only during the membrane formation stage;
LC3-II is detected at each step of autophagosome formation. The
autophagy inhibitor 3-methyladenine (3-MA) acts on the class III
phosphatidylinositol 3-kinase.
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Page 2 of 11lentiviral vectors. Because no shRNAs were available
against LC3, we included shRNAs against GABARAPL1,
a paralogue of LC3 that has been shown to function in
autophagy [23]. All cell lines were tested for inhibition
of HIV-1 replication in three independent experiments
performed in duplicate. Stable cells were challenged
with HIV-1 and the accumulation of CA-p24 in the cul-
ture supernatant was monitored. We measured the aver-
age CA-p24 concentration at peak infection,
corresponding to 10 days post infection. In 14 cell lines
at least a log decrease in CA-p24 levels and thus virus
replication was observed. Inhibition was measured for
the shRNAs ULK1-1 and 4, WIPI1-1 and 3, Beclin1-3,
PIK3R4-3, GABARAPL1-3, Atg3-3, Atg4A-1 and 3,
Atg5-4, Atg10-3 and 5 and Atg12-4 (Figure 2).
To confirm these results, cells freshly transduced with
the suppressive shRNA cassettes were again challenged
with HIV-1. Virus replication was monitored over a per-
iod of 11 days by CA-p24 measurement in the culture
supernatant. Inhibition was confirmed for the shRNAs
WIPI1-1 and Beclin1-3 (Figure 3A) and in an indepen-
dent experiment for PIK3R4-3, Atg4A-1 and 3, Atg5-4,
Atg10-3 and 5 and Atg16-4 (Figure 3B), but HIV-1 inhi-
bition could not be confirmed for other shRNAs
(ULK1-1 and 4, WIPI1-3, GABARAPL1-3, Atg3-3 and
Atg12-4). The Atg16 results do confirm earlier results
on specific inhibition of HIV-1 replication [19]. For
those cases where no inhibition of HIV-1 replication
w a so b s e r v e d ,i tr e m a i n su n c l e a rw h e t h e rt h i si sd u et o
insufficient knockdown of the target ATG or that the
ATG is dispensable for HIV-1 replication. Further
experiments were conducted with the 9 shRNAs against
7 different ATGs that showed a reproducible inhibitory
effect in multiple experiments performed with two inde-
pendently transduced cell samples. In other words, all
shRNAs that caused HIV-1 inhibition in one of the two
experiments were abandoned.
For the selected shRNAs we first determined the ATG
mRNA knockdown efficiency by RT-qPCR (Figure 3C).
The results demonstrate a good knockdown (60-80%)
for PIK3R4, Atg5, Atg10-3 and Atg16. A modest reduc-
tion in mRNA level (40-60%) was scored for Beclin1,
Atg4A-1 and 3 and Atg10-5. For WIPI1 only a small
reduction in mRNA expression (less than 20%) was
measured. These results suggest that the knockdown
level required for HIV-1 inhibition may vary per co-
factor.
We determined the effect of ATG silencing on cellu-
lar autophagy by analyzing the level of LC3-II (LC3
bound to autophagic membranes) in the different cell
lines. The level of LC3-II was analyzed under nutrient-
rich and starvation conditions in the presence and
absence of anti-proteases to analyze the autophagic
flux. Starvation signals lead to conversion of LC3-I to
LC3-II and the presence of protease inhibitors prevents
lysosomal degradation such that LC3-II accumulates in
the cell. Starvation-induced autophagy is functional in
cell lines expressing a shRNA against WIPI, Beclin1
and Atg10. The results are summarized in Table 1. In
contrast, the autophagy flux is impaired in cells
expressing PI3KR4, Atg5 or Atg16 shRNAs. The
autophagy process is dramatically altered when Atg4
expression is shut down.
To score for effects on cell proliferation, we per-
formed the competitive cell growth or CCG assay [24].
For that purpose the puromycin selection marker in
the lentiviral constructs was replaced by the eGFP
marker that allows the detection of transduced cells.
Upon lentiviral-mediated transduction, the mixed cul-
ture of GFP
+ and untransduced GFP
- cells is followed
longitudinally by FACS analysis. Based on the known
doubling time of untransduced GFP
-SupT1 cells, the
decrease in GFP
+/GFP
- ratio over time was used to
calculate the relative cell growth capacity, with the
proliferation of control SHC1 cells set at 100% (Figure
3D). Knockdown of Atg5 has no effect on cell prolif-
eration. A small cell growth reduction of less than 10%
was observed for PIK3R4, Atg4A (both shRNAs) and
Atg10 (both shRNAs). Three shRNAs (Beclin1, WIPI1
and Atg16) induce more significant cytotoxicity with a
10-20% reduced cell growth rate. Beclin1 and WIPI1
were abandoned after this point because the effect on
HIV-1 replication may be caused by the cytotoxic
effect of these shRNAs.
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Figure 2 Screen of shRNAs against 12 autophagy factors. Stable
knockdown cell lines with shRNAs against 12 ATGs were generated
and challenged with HIV-1. Control cells are untransduced SupT1
cells, SHC1 cells (empty vector) and SHC2 cells, expressing a
scrambled shRNA. The screen was repeated twice and each
infection was performed in duplicate. The concentration of viral CA-
p24 protein (ng/ml) in the culture supernatant at peak infection
(day 10) was measured. CA-p24 concentrations were normalized
with the Factor Correction program [39] and the average is plotted,
error bars represent standard deviation from the mean.
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Figure 3 Analysis of HIV-1 replication, ATG-mRNA levels and cell growth in stable knockdown cells. A. Inhibition of HIV-1 replication as
observed in Figure 2 was confirmed in newly generated knockdown cells for Beclin1 and WIPI1. CA-p24 concentration was followed for 10-11
days post infection. B. In a second experiment HIV-1 inhibition was confirmed for PIK3R4-1, Atg4A-1 and 3, Atg5-4, Atg10- 3 and 5 and Atg16-4.
C. The mRNA knockdown was measured with RT-qPCR analysis for the indicated shRNAs. The level measured in the control SHC1 cells was set at
100%. D. Transduced cell mixtures were analyzed in the competitive cell growth assay, which is based on different growth rates of untransduced
GFP
- versus transduced GFP
+ cells. Cell proliferation rates were compared to SHC1 cells, which was set at 100%.
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viral particles
Single cycle infection experiments were performed to
determine which stage of the HIV-1 replication cycle is
blocked in the ATG knockdown cells. Knockdown and
control cells were incubated with HIV-1 for 4 h, the
virus was washed away and new infections were pre-
vented by addition of the fusion inhibitor T1249 to the
culture medium. The percentage of cells positive for
intracellular CA-p24 and the concentration of CA-p24
in the culture supernatant were measured at 48 h post
infection by FACS (Figure 4A). This allows the estab-
lishment of integrated provirus that can express new
viral proteins. For a single shRNA (Atg4A-1) no signifi-
cant difference was measured. For 6 shRNAs a reduc-
tion in both the intracellular and extracellular CA-p24
level was measured: PIK3R4, Atg4A-3, Atg5, Atg10-3,
Atg10-5 and Atg16 (Figure 4B, left and right panel). A
reduction in the number of CA-p24 positive cells means
that less cells were productively infected by HIV-1,
which should also result in reduced CA-p24 levels in
the culture supernatant. The mean production of CA-
p24 per positive cell, shown by the mean fluorescence
intensity (MFI), was not affected (Figure 4B, middle
panel). These combined results indicate an early block
(from virus entry to transcription) in the HIV-1 replica-
tion cycle in these shRNA-expressing cells. To test
whether we indeed probe for early replication steps, the
Reverse Transcriptase drug 3TC and the Integrase inhi-
bitor Raltegravir were tested in single cycle infection
experiments (Figure 4C). This produced a pattern simi-
lar to that of the shAtg cells, that is a reduction in the
percentage of CA-p24 positive cells and CA-p24 con-
centration in the culture supernatant, but no effect on
CA-p24 production per infected cell as measured by the
MFI. We therefore conclude that knockdown of ATG
factors blocks an early HIV-1 replication step.
As an alternative means to inhibit the autophagy path-
way, the autophagy inhibitor 3-methyladenine (3-MA)
was used, which blocks the activity of the PIK3C3 and
PIK3R4 kinases (Figure 1). First, 3-MA was tested in
single cycle infection experiments on wild type SupT1
cells. Cells were pre-treated with 3-MA for 4 h, after
which the drug was washed away before HIV-1 infec-
tion. Alternatively, cells were first infected with HIV-1
and then treated for 48 h. We also tested a combination
of these treatments. All treated cell cultures were com-
pared to the untreated control cells (Figure 4D). As
reported earlier, we observed increased cell death in cul-
tures that were treated with 3-MA for a prolonged per-
iod, including the samples that received 3-MA for 48 h
post infection [17]. Treating cells before infection did
not cause significant changes in cell viability. The con-
centration of CA-p24 in the culture supernatant was
dramatically reduced when cells were treated with 3-
MA after infection (Figure 4D, right panel). However,
more cells in the culture became CA-p24 positive and
the mean production of CA-p24 per actively infected
cell was slightly increased (Figure 4D, left and middle
panel). Thus, cells treated with 3-MA post infection
accumulate CA-p24 and yield a reduced CA-p24 con-
centration in the culture supernatant. These results indi-
cate that a late replication step (from transcription to
budding) is affected by 3-MA treatment after infection.
Simultaneous knockdown of two ATGs enhances HIV-1
inhibition
To test whether the simultaneous knockdown of two
ATGs is tolerated by cells and whether the HIV-1 inhi-
bition can be boosted, we generated double-knockdown
cells expressing shRNAs against Atg16 and Atg5. Atg16
w a sc h o s e na si t sk n o c k d o w nr e s u l t e di ns t r o n gi n h i b i -
tion of HIV-1 replication with limited cytotoxicity [19].
Atg5 knockdown resulted in good inhibition of HIV-1
replication without inducing cytotoxicity. Controls were
untransduced SupT1 cells and the single-knockdown
cell lines. The single knockdown cell lines were actually
also transduced twice; the second transduction was per-
formed with the SHC2 scrambled shRNA control. The
first transduction used lentiviral vectors with the puro-
mycin selection marker, whereas the second transduc-
tion was performed with vectors carrying a GFP-
selection marker. To increase the change of scoring an
additive effect, we purposely transduced cells at a rela-
tively low multiplicity of infection (MOI) of 0.2. This
will yield maximally 1 copy of each shRNA gene con-
struct per doubly transduced cell, thus avoiding satura-
tion of the RNAi mechanism.
Cell lines were challenged with virus and a clear delay
of HIV-1 replication was observed in the double-knock-
down cell line (Figure 5A). In this low MOI setting,
Table 1 Autophagy activity upon ATG knockdown
Targeted ATG Starvation-induced LC3 lipidation Autophagy flux
WIPI1 +
a,b +
Beclin1 + +
PIK3R4 + -
c
Atg4A-1 + +
Atg4A-3 +/-
d -
Atg5 + -
Atg10-3 + +
Atg10-5 + +
Atg16 + -
a Results are representative of two separate experiments
b +; LC3-II increase similar to that in control SupT1 cells
c -; no LC3-II increase
d +/-; minor LC3-II increase
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Figure 4 Single cycle infection experiments. A. ATG knockdown cells were infected with HIV-1 for 4 h, excess virus was washed away and
new infections were prevented by addition of the fusion inhibitor T1249. The percentage of CA-p24 positive cells was measured at 48 post
infection. The live cell population was determined by forward and side scatter (left panels). Cells were intracellularly stained for CA-p24 with a
specific antibody labeled with RD1 (right panels). Mock infected SupT1, infected SupT1 and infected shAtg5 cells are shown as examples. B.
FACS data for all tested cells. The percentage of CA-p24 positive cells was measured at 48 h post infection by FACS (left panel). The mean
production of CA-p24 per positive cell is represented as the mean fluorescence intensity (middle panel). The concentration of CA-p24 in the
culture supernatant was determined by ELISA (right panel). C. To test whether indeed early HIV-1 replication steps were inhibited, the Reverse
Transcriptase 3TC drug and the Integrase inhibitor Raltegravir (RAL) were tested in single cycle infection experiments. D. SupT1 cells were either
mock treated or incubated with 3-MA either starting 4 h before infection or for 48 h post infection, or both. Cells were analyzed for the
percentage of CA-p24 positive cells (left panel), MFI (middle panel) and CA-p24 concentration in the culture supernatant (right panel). All single
cycle infections were performed three times and per experiment every infection was performed in triplicate. A representative experiment is
shown, bars represent the mean and error bars the standard deviation from the mean.
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Figure 5 Additive HIV-1 inhibition by simultaneous knockdown of Atg5 and Atg16. A. Single and double knockdown cell lines were
challenged with HIV-1 and replication was followed over time by measuring CA-p24 in the culture supernatant. B. Relative mRNA expression
levels of Atg5 and Atg16 was determined by RT-qPCR. C. The effect of RNAi-mediated knockdown on cell growth was determined by the
competitive cell growth assay. The percentage cell growth reduction is plotted. D. Single and double knockdown cells were used in single cycle
infections. Cells were analyzed 48 h post infection for the percentage of CA-p24 cells (left panel), MFI (middle panel) and CA-p24 concentration
in the culture supernatant (right panel). E. Autophagy function in the single and double knockdown cells was analyzed in nutrient-rich and
starvation conditions (first 2 bars for each cell line) and for autophagic flux, where the degradation step of autophagy is inhibited by protease
inhibitors (last 2 bars for each cell line). The intensity of the LC3-II signal was corrected for the GAPDH level on Western blot.
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Page 7 of 11HIV-1 replication was not greatly delayed in the single
knockdown cells. Knockdown of Atg5 and Atg16 was
measured by RT-qPCR (Figure 5B) and knockdown of
b o t hA t g 5a n dA t g 1 6w a sc o n f i r m e di nt h ed o u b l e -
knockdown cells. All transduced cells express GFP and
could thus be tested in the competitive cell growth
assay. The cell growth defect of the double-knockdown
cell line is comparable to that observed when Atg16
knockdown is combined with the scrambled shRNA
(Figure 5C). Thus, cell proliferation does not seem ham-
pered more severely by knockdown of two ATGs. In the
single cycle replication assay the additive effect of dou-
ble knockdown of Atg5 and Atg16 was again observed.
Fewer cells became positive for CA-p24 and the concen-
tration of CA-p24 in the culture supernatant was conco-
mitantly reduced when compared to the single-
knockdown cells and SupT1 cells (Figure 5D).
Cells were incubated for 2 h in minimal medium to
generate starvation signals in the absence and presence
of protease inhibitors. The LC3-II level was detected by
Western blot and normalized against the housekeeping
protein GAPDH. Starvation-induced autophagy and
autophagic flux were reduced in the single-knockdown
cells and dramatically reduced in the double-knockdown
cells (Figure 5E).
Discussion
In this study we show that stable RNAi-mediated knock-
down of autophagy factors leads to inhibition of HIV-1
replication. Multiple shRNAs against 13 autophagy fac-
tors (ATGs) were tested and inhibition of virus replica-
tion was scored for 7 ATGs. We confirmed knockdown
of the targeted mRNAs and performed additional cell
proliferation and autophagy tests, which allowed us to
conclude that RNAi against PIK3R4, Atg4A, Atg5 and
Atg16 results in HIV-1 inhibition due to a block of
autophagy. For these 4 ATGs a specific reduction in the
target mRNA expression level and a clear defect in the
autophagy pathway were measured. For Atg10-1 and 3
no block in autophagy was observed, but a specific
reduction in mRNA expression levels was measured and
a minor effect on cell proliferation was observed. It is
possible that the effect on HIV-1 replication is due to a
cellular function of Atg10 other than its role in autop-
hagy. Cell proliferation was not altered upon Atg5
knockdown, and only a small effect on cell growth was
observed for PIK3R4 and Atg4A. Cell proliferation of
Atg16 knockdown cells was 15% reduced compared to
untransduced cells, but for this shRNA a specific reduc-
tion in Atg16 mRNA expression levels and a clear defect
in autophagy were observed. For Beclin1 and WIPI1 a
delay of HIV-1 replication was measured despite the
a b s e n c eo fa ne f f e c to na u t o p h a g y ,a n dt h e s es h R N A s
were therefore not selected for follow-up studies. The
effect on HIV-1 replication could be due to the adverse
effects on cell proliferation. An alternative explanation is
that these specific shRNAs induce an Interferon alpha
(IFNa) response that inhibits HIV-1 replication [25]. An
earlier genome-wide knockdown study has already iden-
tified ATG factors necessary for HIV-1 replication [18],
although this was not confirmed in a second RNAi
screen [26]. However, none of the ATGs for which we
scored inhibition of HIV-1 replication were identified in
the knockdown study by Brass et al., except for Atg16.
In primary cells it has been shown that knockdown of
Beclin1 and Atg5 [20] or Beclin1 and Atg7 [17] results
in inhibition of HIV-1 replication.
When expression of Atg5 and Atg16 was inhibited
simultaneously, additive HIV-1 inhibition was measured.
Knockdown of both ATGs did not have a greater impact
on cell proliferation than that observed in the singly
transduced cells. Atg16 knockdown seems to be the sole
determinant of cell growth delay in the double knock-
down cells, which may be surprising as both Atg5 and
Atg16 are involved in the same step of the autophagy
pathway (Figure 1). Such an additive effect was mea-
sured for autophagy activity, which indicates that the
modest delay in cell growth measured for Atg16 knock-
down is not directly related to the impact on the autop-
hagy pathway.
When ATG knockdown cells were analyzed in single
cycle infection experiments, we observed that less cells
did produce intracellular CA-p24 and the concentration
of CA-p24 in the culture supernatant was concomitantly
reduced. This indicates that less cells became produc-
tively infected. The mean CA-p24 production per CA-
p24 positive cells (mean fluorescence intensity or MFI)
was not affected by ATG knockdown. Thus, fewer cells
are productively infected, but these cells do synthesize
as much CA-p24 as control cells. This result indicates
that ATG knockdown leads to an early block of HIV-1
replication (e.g. entry or reverse transcription).
As an alternative to blocking autophagy with RNAi,
we tested the inhibitor 3-methyladenine (3-MA). Sur-
prisingly, we observed markedly different results in sin-
gle cycle infection experiments with 3-MA compared to
the shRNA-expressing cell lines. First of all, we observed
that a higher percentage of the cells became positive for
intracellular CA-p24, whereas a reduction was measured
in the shRNA-expressing cell lines. As normally a cer-
tain percentage of HIV-1 infections become latent, this
result could indicate that treatment with 3-MA results
in less latently infected cells and more productively
infected cells. A second observation was that cells trea-
ted with 3-MA after HIV-1 infection exhibited an
increased MFI, meaning that cells produced more CA-
p24 per cell than untreated cells. Less CA-p24 was mea-
sured in the culture supernatant. This is similar to what
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that 3-MA mediated blocking of autophagy leads to
inhibition of virus budding into the culture supernatant.
3-MA has been used for several years as a specific inhi-
bitor of autophagy, however, there is accumulating evi-
dence that 3-MA can have pleiotropic effects, and the
impact on autophagy should ideally be confirmed by
alternative means such as shRNAs [27,28].
Autophagy is a cellular pathway that is important in
many viral infections, thus blocking the autophagy path-
way could be of therapeutic value. In addition to viral
infections, blocking autophagy has been proposed as a
new therapeutic approach against cancer. Cancerous
cells appear to exhibit increased autophagy activity that
provides a survival mechanism when the cell is treated
with chemotherapy [29]. Blocking autophagy with 3-MA
in combination with anti-cancer drugs has been used
against several types of cancer, e.g. breast and colorectal
cancer, and siRNAs to silence the ATGs Beclin1 and
Atg5 have been tested against cervical cancer [30-32].
Therefore RNAi-mediated knockdown of autophagy fac-
tors could be of therapeutic value against viruses and
other diseases. In this study, we used lentiviral vector-
mediated delivery of shRNAs and this delivery system
provides an attractive possibility to develop a durable
therapy for HIV-1 patients. The ex vivo transduction of
hematopoietic stem cells with lentiviral vectors expres-
sing anti-viral and/or anti-co-factor shRNAs should
guarantee the life-long generation of HIV-1 resistant
cells, e.g. T cells and monocytes. This approach is the
focus of further studies in our laboratory.
Methods
DNA constructs
pLKO.1 DNA constructs expressing a specific shRNA
were from the MISSION™ TRC-Hs 1.0 library [33].
Constructs including the negative control constructs
SHC001 and SHC002 (hereafter named SHC1 and
SHC2) were obtained from Sigma-Aldrich as bacterial
clones. Plasmid DNA was extracted using the Nucleo-
bond Midiprep columns according to the manufacturer’s
instructions (Macherey-Nagel). Target sequences can be
found on the website of Sigma-Aldrich [http://www.sig-
maaldrich.com/life-science/functional-genomics-and-
rnai/shrna/individual-genes.html]. The pLKO.1 con-
structs from the MISSION™ TRC-Hs 1.0 library con-
tain a puromycin selection marker, which was replaced
with the gene for enhanced eGFP (eGFP) as described
earlier [24]
Chemicals
The T1249 peptide (WQEWEQKITALLEQAQIQQE-
KNEYELQKLDKWASLWEWF, Pepscan Therapeutics)
was obtained as 10 000 × stock solution [34]. The
autophagy inhibitor 3-MA (Sigma-Aldrich) was diluted
in 70% methanol and used at a final concentration of 10
mM. Protease inhibitors pepstatin A and E64d and the
anti-LC3 antibody were purchased from Sigma-Aldrich.
Raltegravir (MK-0518) was obtained from Bio-Connect
services [35] and used at a final concentration of 1 nM.
Lamivudine (3TC) was obtained from GlaxoWellcome
and used at a final concentration of 33 pM.
Cell lines
T h eh u m a ne m b r y o n i ck i d n e yc e l ll i n eH E K 2 9 3 Tw a s
grown in DMEM, supplemented with 10% FCS, 100 U/
ml penicillin and 100 μg/ml streptomycin. The human
T cell line SupT1 was cultured in Roswell Park Memor-
ial Institute (RPMI) medium, supplemented with 10%
FCS, 100 U/ml penicillin and 100 μg/ml streptomycin.
Lentiviral vector production and generation of stable
knockdown cell lines
Lentiviral vectors were produced as described earlier
[36]. In short, HEK293T cells were co-transfected with
pLKO.1-shRNA and the packaging plasmids (pVSV-G,
pMDL and pRev-RRE) with Lipofectamin 2000 (Invitro-
gen). The medium was refreshed 1 day after transfection
and the culture supernatant was harvested the next day.
Aliquots of the culture supernatant with the lentiviral
vectors were stored at -80°C. A sample was tested in
CA-p24 ELISA.
SupT1 cells were seeded in 24-wells format at 1 × 10
5
cells/well and transduced with a fixed amount of lenti-
viral vector. Excess virus was washed away 1 day after
transduction and selection of stably transduced cells was
started by adding puromycin to the medium at a final
concentration of 1 μg/ml. In the case of GFP-expressing
cell lines, transduced cells were FACS sorted.
CA-p24 ELISA
Culture supernatant was heat-inactivated at 56°C for 30
min in the presence of 0.05% Empigen-BB (Calbiochem).
The CA-p24 concentration was determined by a twin-
site ELISA with D7320 (Biochrom) as the capture anti-
body and the alkaline phosphatase-conjugated anti-CA-
p24 monoclonal antibody EH12-AP (International
Enzymes) as the detection antibody. Detection was per-
formed with the Lumiphos plus system (Lumigen) in a
LUMIstar Galaxy luminescence reader (BMG Lab-
technologies). Recombinant CA-p24 produced in a
baculovirus system was used as reference standard.
HIV-1 replication and single cycle infection
The HIV-1 molecular clone HIV-1LAI [37] was used to
produce virus by transfection of HEK293T cells. HIV-1
production was measured by CA-p24 analysis in the cul-
ture supernatant. For HIV-1 replication studies, SupT1
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5 cells/well
and infected with HIV-1 (0.2 ng CA-p24). HIV-1 repli-
cation was monitored by scoring for syncytia formation
and longitudinal measurement of CA-p24 production in
the culture supernatant.
For single cycle infection experiments SupT1 cells
were incubated with HIV-1 for 4 hours. Excess virus
was washed away and the cells were cultured in the pre-
sence of entry inhibitor T1249 (Pepscan) to block subse-
quent rounds of viral entry. Intracellular CA-p24 was
analyzed by FACS and extracellular CA-p24 was mea-
sured by ELISA at 48 h post infection.
Competitive cell growth assay and flow cytometry
To assess the cytotoxicity induced by knockdown of
autophagy factors, we used the competitive cell growth
or CCG assay as described earlier [24]. In brief, SupT1
cells were transduced with 0.1 or 1 μll e n t i v i r a lv e c t o r
that expresses a shRNA and the GFP selection marker.
The percentage of cells expressing GFP in the transduc-
tion mixture was analyzed longitudinally by FACS analy-
s i s .T w i c ew e e k l yas a m p l eo ft h ec u l t u r ew a st a k e n ,
cells were collected by centrifugation (4 min at 4,000
rpm, Eppendorf centrifuge) and resuspended in FACS
solution (Phosphate buffered saline (PBS) + 2% FCS)
and analyzed on FACScanto (BD Biosciences). The live
cell population was determined with forward and side
scatter. Fluorescence was normalized using unstained
SupT1 cells. Based on the known doubling time of
untransduced cells, the change in GFP
+/GFP
- ratio over
the course of the experiment can be used to calculate
the cell growth defect (%) of the GFP
+ transduced cells
[24].
For intracellular CA-p24 staining, cells were collected
by centrifugation (4 min at 4,000 rpm, Eppendorf centri-
fuge) and fixed in 250 μl 4% formaldehyde for 5 min at
room temperature. Cells were permeabilized with 500 μl
BD Perm/Wash™ buffer (BD Pharmingen) and stained
f o ra tl e a s t1ha t4 ° Ci n5 0μlB DP e r m / W a s h ™ buffer
containing 5 μl 1:100 diluted antibody against CA-p24
conjugated with PE (monoclonal mouse, clone KC57,
Coulter). Excess antibody was washed away by washing
twice with 500 μl FACS solution, cells were resuspended
in 250 μl FACS solution and analyzed on a FACScanto.
Uninfected and unstained samples were used as negative
controls.
RT-qPCR
mRNA knockdown levels for specific ATG targets were
analyzed by RT-qPCR. RNA was isolated from 0.5 × 10
6
cells with the RNeasy kit (Qiagen) according to the
manufacturer’s protocol, including the DNase I treat-
ment on the column. 1 μg RNA was used for reverse
transcription (Thermoscript, Invitrogen) with Oligo-dT
primers and cDNA synthesis was performed at 50°C.
The cDNA was diluted 100 times and 5 μl of the diluted
sample was used as template in a SYBR Green based
RT-qPCR (SYBR Green FAST PCR, Qiagen) with an
ABI Prism 7,000 detection system (Applied Biosciences).
Primers for target genes and the internal control b-actin
were from the Quantitect primer assays (Qiagen). The
ΔΔCt method was used to calculate relative mRNA
expression as described earlier [38].
Analysis of autophagy
Autophagy was induced by nutrient starvation (EBSS) for
2 h in presence or absence of the lysosome protease inhi-
bitors E64d and pepstatin A (10 μg/ml each) to analyze
the autophagy flux. To monitor the induction of autop-
hagy, the relative amount of the PE-conjugated form
(LC3-II) was determined by immunoblot analysis of
whole-cell lysate using a rabbit polyclonal antibody against
LC3. Cells were washed twice in PBS and lysed in buffer
containing 50 mM Tris-HCl (pH 8), 1% Triton X-100, 100
mM NaCl, 1 mM MgCl2, 150 mM PMSF, and complete
mini protease inhibitor cocktail (Roche Diagnostics). Cell
lysates were electrophoresed in 12% SDS-PAGE and
blotted to PVDF membranes. After a blocking step with
PBS and 0.5% casein for 1 h at room temperature, blots
were incubated overnight at 4°C with the anti-LC3 anti-
body in the blocking buffer. After 3 washes with PBS and
0.05% Tween, the blots were incubated for 1 h at room
temperature with peroxidase-coupled antiserum diluted in
blocking buffer. After further washes, the immune com-
plexes were revealed by ECL (Millipore). The image cap-
ture was taken by the G:BOX camera system (Syngene)
and intensity of the signals was analyzed with GeneTools
software. The LC3-II signal was compared to that of the
control housekeeping protein GAPDH.
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